Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection.

< BACK TO ARCHIVE


2020 May


J Gastroenterol Hepatol


http://www.ncbi.nlm.nih.gov/pubmed/31609495?dopt=Abstract


35


5

Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection.

Authors

Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, et al.
J Gastroenterol Hepatol. 2020 May; 35(5):855-861.
PMID: 31609495.

Abstract

In clinical trials, a pangenotype direct-acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy and tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings in real-world settings, focusing on patients with cirrhosis, history of DAA failure, or HCV genotype 3 who were treated with a 12-week regimen, in a large multicenter study from Japan.
Read This Paper